Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Deferred Tax (2016)

Myriad Genetics (MYGN) has disclosed Long-Term Deferred Tax for 7 consecutive years, with $12.7 million as the latest value for Q2 2016.

  • Quarterly Long-Term Deferred Tax changed N/A to $12.7 million in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Jun 2016, changed N/A year-over-year, with the annual reading at $12.7 million for FY2016, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q2 2016 was $12.7 million at Myriad Genetics, down from $13.5 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $30.6 million in Q2 2012, with the low at $407000.0 in Q1 2015.
  • Average Long-Term Deferred Tax over 5 years is $21.3 million, with a median of $27.0 million recorded in 2012.
  • The sharpest move saw Long-Term Deferred Tax rose 21.93% in 2013, then crashed 88.82% in 2014.
  • Over 5 years, Long-Term Deferred Tax stood at $24.6 million in 2012, then grew by 21.93% to $30.0 million in 2013, then tumbled by 89.33% to $3.2 million in 2014, then soared by 321.88% to $13.5 million in 2015, then decreased by 5.93% to $12.7 million in 2016.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $12.7 million, $13.5 million, and $407000.0 for Q2 2016, Q4 2015, and Q1 2015 respectively.